At the Oncobiome Lab, we investigate the emerging role of intratumoral microorganisms in cancer biology, with a primary focus on pancreatobiliary malignancies. Our research explores how the diverse microbial communities within tumors influence cancer hallmarks, disease progression, and treatment response.
We are particularly focused on understanding the mechanistic relationships between specific microbial signatures, their metabolites and cancer biology. By mapping these complex interactions at the molecular level, we aim to identify novel biomarkers and therapeutic targets that can be leveraged for precision oncology approaches.
We employ cutting-edge technologies including multi-omics analysis of patient cohorts, advanced imaging, and innovative in vitro and in vivo models to characterize the oncobiome and its functional impact. Through close collaboration with clinical partners and the Molecular Tumorboard Tuebingen, we work to translate our discoveries into practical applications that can improve diagnosis, treatment selection, and patient outcomes.
The ultimate vision of our lab is to harness our understanding of the oncobiome to develop personalized therapeutic strategies that target the unique microbial-host interactions within each patient's tumor, advancing the field of precision medicine in pancreatobiliary cancers.
